The cost‐effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain
Rattachement africain : es. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Invasive mould diseases are associated with high morbidity, mortality and economic impact. Its treatment is often started prior to differential pathogen diagnosis. Isavuconazole is approved for treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) when amphotericin-B is not indicated. OBJECTIVES: To estimate the cost-effectiveness of isavuconazole vs voriconazole for the treatment of adult patients with possible IA prior to differential pathogen diagnosis, in Spain. METHODS: A decision tree analysis was performed using the Spanish Healthcare System perspective. Among all patients with possible IA, it was considered that 7.81% actually had IM. Costs for laboratory analysis, management of adverse events, hospitalisation and drugs per patient, deaths and long-term effects in life years (LYs) and quality-adjusted LYs (QALYs) were considered. Efficacy data were obtained from clinical trials and utilities from the literature. Deterministic and probabilistic sensitivity analyses (PSA) were conducted. RESULTS: In patients with possible IA and when compared to voricanozole, isavuconazole showed an incremental cost of 4758.53€, besides an incremental effectiveness of +0.49 LYs and +0.41 QALYs per patient. The Incremental Cost Effectiveness Ratio was 9622.52€ per LY gained and 11,734.79€ per QALY gained. The higher cost of isavuconazole was due to drug acquisition. Main parameters influencing results were mortality, treatment duration and hospitalisation days. The PSA results showed that isavuconazole has a probability of being cost-effective of 67.34%, being dominant in 24.00% of cases. CONCLUSIONS: Isavuconazole is a cost-effective treatment compared to voriconazole for patients with possible IA for a willingness to pay threshold of 25,000€ per additional QALY.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The cost‐effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain
- Date Crossref
- 30/10/2020
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Clinica Universidad de Navarra pays non établi dans la noticeÉtablissement de santé
-
Universitat Autònoma de Barcelona pays non établi dans la noticeUniversité ou école supérieure
-
Complejo Hospitalario de Salamanca pays non établi dans la noticeÉtablissement de santé
-
Universidad de Oviedo pays non établi dans la noticeUniversité ou école supérieure
-
Pfizer (Spain) pays non établi dans la noticeEntreprise
-
Pharmacoeconomics and Health Outcomes Research Iberia (Spain) pays non établi dans la noticeEntreprise
-
Hematology Department Hospital Clínico Universitario de Salamanca Salamanca Spain pays non établi dans la noticeÉtablissement de santé
-
Ingress‐health Oviedo Spain pays non établi dans la noticeInstitution
-
Ingress-health pays non établi dans la noticeInstitution
-
Pharmacoeconomics Department Pfizer Madrid Spain pays non établi dans la noticeInstitution
-
Medical Department Pfizer Madrid Spain pays non établi dans la noticeInstitution
Clinica Universidad de Navarra, Universitat Autònoma de Barcelona et Complejo Hospitalario de Salamanca, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.